Home
Home

brentuximab vedotin

Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL

Takeda seeks Japanese approval for brentuximab vedotin to treat relapsed/refractory CD30 positive HL and ALCL
Pharmabiz

The Big Bet on Seattle Genetics

The Big Bet on Seattle Genetics
Motley Fool

FDA committee to review Seattle Genetics cancer drug applications in July

FDA committee to review Seattle Genetics cancer drug applications in July
bizjournals.com

Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association

Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association
Yahoo/BusinessWire

Seattle Genetics says FDA will make two rulings on its cancer drug brentuximab by Aug. 30

Seattle Genetics says FDA will make two rulings on its cancer drug brentuximab by Aug. 30
Yahoo/AP

News

Biotech Calendar: FDA Drug Approvals in 2011
TheStreet.com

News

Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Yahoo/BusinessWire

News

Is Seattle Genetics the Next Big Thing?
Minyanville

News

Now That's What I Call a Drug That Works (Seattle Genetics)
Motley Fool
»

News

Seattle Genetics, Takeda & Millennium begin phase-III Aethera trial of brentuximab vedotin for post-transplant Hodgkin lymphoma
Pharmabiz
»